logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

G/GEJ cancer: nivolumab + SOX/CapeOX does well in ATTRACTION-4

ORR was 57.1% and 76.5% with nivolumab plus SOX and CapeOX, respectively.